ARTICLE | Clinical News
Junovan regulatory update
October 30, 2006 8:00 AM UTC
IDMI submitted an NDA to FDA for Junovan plus chemotherapy to treat newly diagnosed resectable high-grade osteosarcoma following surgical resection. The company requested Priority Review for the muram...